My Interprofessional Care Team for Adherence and Research Engagement Disparities
Pharmacist-CHW Team to Improve Medication Adherence and Reduce Hypertension
University of Arizona
217 participants
Aug 30, 2023
INTERVENTIONAL
Conditions
Summary
MI-CARE is an innovative coordinated care team intervention to improve medication adherence and blood pressure derived from research findings that build on existing clinical practice. Designed with an eye toward sustainability, MI-CARE incorporates billable pharmacist and CHW services for patients with low medication adherence and high burdens of chronic illness and preventable consequences. MI-CARE offers interprofessional team care with comprehensive expertise and complementary skill sets that mitigate the silo effect of specialized medicine to deliver primary care to diverse, high-risk populations experiencing disparities in hypertension.
Eligibility
Inclusion Criteria7
- age ≥ 18 years;
- self-report cultural identity as African-American, or Latino;
- speak English, or Spanish;
- have medication-treated hypertension;
- use ≥5 chronic medications;
- have hypertension medication adherence \<85%; and
- able to provide informed consent.
Exclusion Criteria2
- if project staff conclude that a candidate participant is unable to comprehend the informed consent process (because he/she offers an inappropriate response to consent questions); or
- if the candidate is hostile or unwilling to follow project protocols.
Interventions
MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Months 1-2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05470439